KPV: the smallest active fragment of α-MSH studied for the NF-κB pathway
Three amino acids, no melanocortin affinity, but a reported action on the inflammatory NF-κB pathway: what the literature documents about KPV.
KPV is the C-terminal tripeptide of α-MSH (residues 11-13, Lys-Pro-Val) — one of the smallest peptide fragments studied in the literature on inflammation modulation.
A fragment without melanocortin activity
A distinctive point highlighted by the literature: unlike full-length α-MSH or analogs such as Melanotan II, KPV shows no significant affinity for melanocortin receptors (MC1R to MC5R). Its reported mechanism of action is mainly intracellular, independent of the family's classic receptor-mediated signaling.
Inhibition of the NF-κB pathway
Studies (PMID 18789754, PMC2241650) describe an inhibition of the NF-κB pathway through direct interaction with the p65/p50 subunits of the complex. NF-κB is a central transcription factor of the cellular inflammatory response; its reported inhibition by KPV leads to a reduction in the production of the pro-inflammatory cytokines IL-1β, TNF-α, IL-6, and IL-8 in the models studied.
Effects on chemotaxis and IκB signaling
In vitro, KPV decreases neutrophil chemotaxis (their migration toward an inflammatory site) and reduces IκB phosphorylation, the natural inhibitor of NF-κB whose phosphorylation typically precedes activation of the inflammatory pathway.
Effects on the intestinal epithelial barrier
A particular research axis concerns the effect of KPV on the tight junctions of the intestinal epithelium: published work describes a reinforcement of these junctions in vitro, a mechanism studied in relation to intestinal barrier integrity. Direct antimicrobial effects have also been documented.
A component of the KLOW blend
KPV is a component of the KLOW blend, where its function as an NF-κB inhibitor is studied as complementary to the other three components (GHK-Cu, BPC-157, TB-500), which focus on angiogenesis and matrix remodeling rather than inflammation resolution.